A synthetic biology drug discovery company that maps receptor pathway activity at scale to design multi-target small molecules for complex diseases.
OpenADMET / Open Molecular Software Foundation / Octant / UCSF
Released December 9, 2025
ADMET property prediction for CYP inhibition, PXR activation, hERG, microsomal clearance, and permeability, all trained on public assay data.